PerkinElmer (PKI) Earning Somewhat Positive News Coverage, Analysis Finds
Media stories about PerkinElmer (NYSE:PKI) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. PerkinElmer earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 45.6819319895811 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s rankings:
- PerkinElmer, Inc. (PKI) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- PerkinElmer Launches New IVIS® Lumina™ S5 and Lumina X5 systems for High Throughput In Vivo Imaging (labmanager.com)
- PerkinElmer Launches QSight®210 MD System for Clinical Laboratories (tmcnet.com)
- PerkinElmer Extends Clinical Whole Genome Sequencing Services (advfn.com)
PKI has been the subject of a number of recent analyst reports. BidaskClub cut shares of PerkinElmer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 14th. Cantor Fitzgerald set a $65.00 price target on shares of PerkinElmer and gave the company a “hold” rating in a research report on Monday, June 19th. Cowen and Company reiterated a “market perform” rating and set a $70.00 price target (up from $61.00) on shares of PerkinElmer in a research report on Tuesday, June 20th. Jefferies Group LLC reiterated a “hold” rating and set a $69.00 price target (up from $58.00) on shares of PerkinElmer in a research report on Tuesday, June 20th. Finally, Evercore ISI reiterated an “in-line” rating and set a $68.00 price target (up from $62.50) on shares of PerkinElmer in a research report on Thursday, June 22nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $67.00.
Shares of PerkinElmer (PKI) traded down 0.04% on Wednesday, reaching $68.53. 664,986 shares of the company were exchanged. The stock has a market capitalization of $7.55 billion, a PE ratio of 20.67 and a beta of 0.74. The company has a 50-day moving average price of $65.71 and a 200 day moving average price of $62.70. PerkinElmer has a 1-year low of $45.35 and a 1-year high of $70.16.
PerkinElmer (NYSE:PKI) last posted its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.67. The firm had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The company’s revenue was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS. On average, analysts forecast that PerkinElmer will post $2.89 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 10th. Investors of record on Friday, October 20th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date of this dividend is Thursday, October 19th. PerkinElmer’s dividend payout ratio (DPR) is presently 8.46%.
In other PerkinElmer news, insider Andrew Okun sold 4,358 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $65.00, for a total value of $283,270.00. Following the completion of the sale, the insider now owns 16,799 shares of the company’s stock, valued at $1,091,935. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is owned by company insiders.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.